Last reviewed · How we verify
INH RIF Rifb PZA EMB AZT 3TC D4T EFV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
INH RIF Rifb PZA EMB AZT 3TC D4T EFV (INH RIF Rifb PZA EMB AZT 3TC D4T EFV) — Shanghai Public Health Clinical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| INH RIF Rifb PZA EMB AZT 3TC D4T EFV TARGET | INH RIF Rifb PZA EMB AZT 3TC D4T EFV | Shanghai Public Health Clinical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- INH RIF Rifb PZA EMB AZT 3TC D4T EFV CI watch — RSS
- INH RIF Rifb PZA EMB AZT 3TC D4T EFV CI watch — Atom
- INH RIF Rifb PZA EMB AZT 3TC D4T EFV CI watch — JSON
- INH RIF Rifb PZA EMB AZT 3TC D4T EFV alone — RSS
Cite this brief
Drug Landscape (2026). INH RIF Rifb PZA EMB AZT 3TC D4T EFV — Competitive Intelligence Brief. https://druglandscape.com/ci/inh-rif-rifb-pza-emb-azt-3tc-d4t-efv. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab